Morad Vivian, Abrahamsson Annelie, Dabrosin Charlotta
Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
J Clin Endocrinol Metab. 2014 Sep;99(9):3460-7. doi: 10.1210/jc.2014-1129. Epub 2014 May 5.
Exposure to sex steroids is associated with increased breast cancer risk, and adipokines, leptin and adiponectin have been implicated in cancer progression. However, it is not known whether sex steroids affect adipokine secretion in breast tissue.
To elucidate the role of estrogen and tamoxifen on adipokine release in normal human breast tissue and breast cancer.
Microdialysis sampling was used to collect extracellular in vivo leptin and adiponectin from normal human breast tissue in premenopausal healthy volunteers during the menstrual cycle and in postmenopausal women before tamoxifen treatment and after 6 weeks of treatment. In women with breast cancer, microdialysis was performed intratumorally before surgery. In addition, whole normal breast tissue biopsies were cultured ex vivo, and murine breast cancer models were evaluated.
In normal breast tissue, plasma estradiol negatively correlated with local extracellular adiponectin levels (r = -0.34; P < .05) and positively correlated with leptin (r = 0.37; P < .05) and leptin:adiponectin ratio (r = 0.38; P < .05). In postmenopausal women, tamoxifen treatment increased adiponectin (P < 0.05) and decreased leptin (P < .01) and the leptin:adiponectin ratio (P < .01). These in vivo results were confirmed in breast tissue biopsies cultured ex vivo. In patients with breast cancer, extracellular leptin was higher (P < .01) and adiponectin lower (P < .05) in tumors than in normal adjacent breast tissue. In a murine model of breast cancer, estrogen exposure increased leptin secretion (P < .05).
Estrogen exposure may have a critical role in the regulation of adipokines in human breast tissue and may serve as therapeutic targets for treatment and prevention.
接触性类固醇与乳腺癌风险增加有关,脂肪因子、瘦素和脂联素与癌症进展有关。然而,尚不清楚性类固醇是否会影响乳腺组织中脂肪因子的分泌。
阐明雌激素和他莫昔芬对正常人乳腺组织和乳腺癌中脂肪因子释放的作用。
采用微透析采样法,在月经周期中收集绝经前健康志愿者正常乳腺组织中的细胞外瘦素和脂联素,以及绝经后妇女在接受他莫昔芬治疗前和治疗6周后的细胞外瘦素和脂联素。对于乳腺癌患者,在手术前进行瘤内微透析。此外,对正常乳腺组织活检标本进行体外培养,并对小鼠乳腺癌模型进行评估。
在正常乳腺组织中,血浆雌二醇与局部细胞外脂联素水平呈负相关(r = -0.34;P < 0.05),与瘦素呈正相关(r = 0.37;P < 0.05),与瘦素:脂联素比值呈正相关(r = 0.38;P < 0.05)。在绝经后妇女中,他莫昔芬治疗可增加脂联素水平(P < 0.05),降低瘦素水平(P < 0.01)和瘦素:脂联素比值(P < 0.01)。这些体内结果在体外培养的乳腺组织活检中得到证实。在乳腺癌患者中,肿瘤组织中的细胞外瘦素水平较高(P < 0.01),脂联素水平较低(P < 0.05)。在小鼠乳腺癌模型中,雌激素暴露可增加瘦素分泌(P < 0.05)。
雌激素暴露可能在调节人乳腺组织中的脂肪因子方面起关键作用,并可能成为治疗和预防的靶点。